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Summa.ry 
When merozoites of the malaria parasite Plasmodiumfaki~rum  are released from infected erythrocytes 
and invade new red cells, a component of a protein complex derived from the merozoite surface 
protein 1 (MSP-1) precursor undergoes a single proteolytic cleavage known as secondary processing. 
This releases the complex from the parasite surface, except for a small membrane-bound fragment 
consisting of two epidermal growth factor (EGF)-like domains, which is the only part of MSP-1 
to be carried into invaded erythrocytes. We report that,  of a group of monoclonal antibodies 
specific for epitopes within the EGF-like domains, some interfere with secondary processing whereas 
others do not. Those that most effectively inhibit processing have previously been shown to 
prevent invasion. Other antibodies, some of which can block this inhibition, not only do not 
prevent invasion but are carried into the host cell bound to the merozoite surface. These observations 
unequivocally demonstrate that the binding of antibody to the COOH-terminal region of MSP-1 
on the merozoite surface may not be su~cient to prevent erythrocyte invasion, and show that 
the interaction of different antibodies with adjacent epitopes within the EGF-like domains of 
MSP-1 can have distinct biochemical effects on the molecule. Inhibition of MSP-1 processing 
on merozoites may be a mechanism by which protective antibodies interrupt the asexual cycle 
of the malaria parasite. 
T 
he blood-stage malaria parasite replicates within host 
erythrocytes. At periodic intervals, parasitized cells rup- 
ture to release infectious merozoite progeny which rapidly 
reinvade fresh erythrocytes. The initial interaction between 
merozoite and red cell involves ligands on the merozoite sur- 
face (1),  and  it  is  widely documented that  antibodies  to 
merozoite surface proteins (MSPs) can interfere with parasite 
growth in vitro (2-9) and in vivo (10-12). In some cases these 
antibodies act by directly agglutinating released merozoites 
(7). However, in the majority of cases reported, the mecha- 
nisms involved are unknown. 
A major component of the merozoite surface is a protein 
complex containing  proteolytic fragments  of the  MSP-1 
precursor (13). After merozoite release, a secondary processing 
event occurs in which the membrane-bound 42-kD compo- 
nent (MSP-142) of this complex is subjected to a single pro- 
teolytic cleavage  (14,  15).  The NH2-terminal,  33-kD clea- 
vage product (MSP-133)  is shed with the remainder of the 
complex (16), whereas the COOH-terminal, 19-kD fragment 
(MSP-119), which consists of two epidermal growth factor 
(EGF)-like domains, remains on the merozoite (2,  14) (see 
Fig.  1).  Secondary processing goes to completion when a 
merozoite successfully invades an erythrocyte (2,  17). Pro- 
cessing also takes place in free merozoites isolated from cul- 
ture, allowing the development of an assay which we have 
used to partially characterize the protease responsible (16, 17). 
We have postulated that secondary processing may be an es- 
sential step in erythrocyte invasion, and were therefore in- 
terested in specific inhibitors of the proteolysis. 
In this study, a group of IgG mAbs reactive with epitopes 
within the EGF-like domains of MSP-1 was screened for their 
ability to interfere with secondary processing. 
Materials  and Methods 
Parasites.  Plasmodiumfakiparum,  strain FCB-1 and clone T9/96, 
was maintained in culture and synchronized as described previously 
(16,  17). 
Antibodies.  mAbs 12.8, 12.10, 7.5, and 2.2 have been described 
previously (2, 13), as have mAbs 111.4, 111.2, and 89.1 (18, 19). 
mAbs 1E1, 2F10, and 12Dll were produced recently in this labora- 
tory (20). With the exception ofmAb 89.1, all the antibodies recog- 
nize disulphide-constrained epitopes within the EGF-like domains 
of MSP-1 (see Fig. 1) as shown by their reactivity on Western blots 
with native (21) or recombinant (20, 22) MSP-119 in a nonreduced 
but not a reduced form. All mAbs were purified by affinity chro- 
matography on protein A or protein G-Sepharose, and dialyzed 
exhaustively against PBS, pH 7.2, containing  1 mM CaC12 and 
1 mM MgCh (PBS Ca/Mg) before use. 
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Figure  1.  Schematic  showing secondary  processing  of the P.fakiFarum 
MSP-1. (A) MSP-1 is present on the newly released merozoite surface as 
a complex of four polypeptides of •83,  30, 38, and 42 kD (MSP-ls3, 
MSP-13o, MSP-13s, and MSP-142). MSP-142  (derived from the COOH ter- 
minus of the precursor; shaded) is membrane bound through a glycosyl 
phosphatidylinositol anchor. (/3) At or just before erythrocyte invasion, 
cleavage of MSP-142 between Leu1630 and Asn1631 (numbering based on 
the deduced  amino acid sequence of the complete  MSP-1 gene; 15) produces 
MSP-133 and MSP-119 and releases the complex from the merozoite sur- 
face. MSP-119  is represented as two EGF-like modules. A quantitative anal- 
ysis of the processing (17) has shown that MSP-142 is stoichiometrically 
converted to MSP-133. All the mAbs used in this study bind epitopes 
within MSP-119, except mAb 89.1, which recognizes  an epitope on MSP- 
ls3 (16, 19). 
Production of a rabbit antiserum against a recombinant protein 
corresponding to the NH2-terminal  region of MSP-142 has been de- 
scribed  previously (17). The antiserum recognizes both MSP-142 
and MSP-133, but not MSP-119. 
Merozoite Production.  Mature FCB-1 schizonts were enriched 
from synchronous cultures by flotation on Plasmagel,  and natu- 
rally released merozoites were isolated  by membrane filtration as 
previously described (17, 23). Giemsa-stained smears of  the merozoite 
preparations consistently indicated  the complete absence  of con- 
taminating schizonts or uninfected erythrocytes. 
Assays of MSP-1 Secondary Processing.  Secondary processing  of 
MSP-1 in preparations of merozoites, and the effects of anti-MSP-1 
mAbs on it, was assayed using the immunoblot method described 
previously (16, 17). Briefly, freshly isolated merozoites were washed 
in ice-cold  PBS Ca/Mg, divided  on ice into aliquots  containing 
~2  x  109 merozoites each,  and supplemented  with either buffer 
only or purified  mAb to a final antibody concentration of 400/xg 
ml-1.  One aliquot supplemented with buffer only was immedi- 
ately solubilized in SDS; all other samples were incubated at 37~ 
for 1 h to allow secondary processing to occur before solubiliza- 
tion. All samples were then subjected  to SDS-PAGE under non- 
reducing conditions on a 12.5% gel, electrophoreticaUy transferred 
to nitrocellulose,  and the blot probed with the rabbit antiserum 
to MSP-133. 
The above methodology was modified to assess the ability  of 
antibodies  which did not affect processing,  to competitively block 
the activity of those that did. Aliquots of washed  merozoites on 
ice were supplemented with either buffer only or purified  mAb 
to a final antibody concentration of 400 #g ml- 1. After a 15-min 
incubation (pretreatment)  on ice, samples were further supplemented 
with processing inhibitory mAbs 12.8 or 12.10, or 1El  (400/~g 
m1-1  final  concentration),  placed  at  37~  for  1 h,  then  SDS- 
solubilized  and analyzed  by immunoblot as described  above. 
Merozoite lnvasion Inhibition Tests.  These were carried out as de- 
scribed  previously (2). 
Analysis of Newly Parasitized Erythrocytes  for the Presence of Anti- 
bodies Carried in on Invading Merozoites.  Mature schizonts were en- 
riched from synchronous cultures by flotation on Plasmagel  (17) 
or centrifugation over 63% isotonic Percoll (21) and added to fresh 
erythrocytes to obtain a final parasitaemia  of 10%. The cells were 
resuspended  to a 5% hematocrit in culture medium, divided into 
aliquots,  then supplemented with either culture medium only or 
purified mAbs, previously dialyzed against culture medium. Final 
mAb concentration in these cultures was 500/zg m1-1. After in- 
cubation at 37~  for 4 h to allow merozoite release and erythro- 
cyte invasion,  residual  schizonts were removed by three cycles of 
centrifugation  over 67.5% isotonic PercoU (2). The resulting prepa- 
rations,  containing only uninfected erythrocytes and newly para- 
sitized cells, were washed twice in medium containing 5% FCS, 
smeared  onto  slides, air-dried,  and  acetone fixed.  Intracellular, 
parasite-associated  antibody was visualized by incubation of fixed 
preparations  with a FITC-conjugated goat anti-mouse IgG anti- 
body (Sigma Chemical Co., St. Louis, MO) diluted  1:100 in PBS 
containing 5% vol/vol FCS. Slides were counterstained with 0.01% 
wt/vol Evans blue in PBS, and examined by fluorescence microscopy. 
Figure 2.  Secondary  processing 
of MSP-1 is inhibited by some but 
not all mAbs specific to epitopes 
within  the  EGF-like  domains. 
Shown is processing of MSP-142 in 
isolated, freshly  washed merozoites 
(lane I); after further incubation of 
the merozoites at 37~  in the ab- 
sence of  added antibody (lane 2); or 
in the presence  of  purified mAbs 2.2 
(lane 3), 7.5 (lane 4), 12.8 (lane 5), 
12.10 (lane 6), 2F10 (lane 7), 12Dll 
(lane 8), 1E1 (lane 9), 111.4  (lane I0), 
111.2 (lane 11), and 89.1 (lane 12). 
Secondary  processing  is indicated by 
the  appearance of a  band corre- 
sponding to MSP-133, and a con- 
comitant decrease in the intensity 
of the MSP-142 band. 
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All  the  anti-MSP-ll9  mAbs used  in  this  study bind  to 
the surface of unfixed merozoites, and to acetone-permeabil- 
ized newly invaded  (ring-stage)  parasites  as  ascertained by 
indirect  immunofluorescence assays  (data not shown).  Fig. 
2  shows  that  only three  of the mAbs inhibited  secondary 
processing on merozoites. All three mAbs also induced some 
abnormal processing, resulting in a slightly truncated form 
of MSP-133  in addition  to or instead  of the usual product. 
Inhibition was dose dependent and detectable at antibody con- 
centrations as low as 40/zg m1-1 in the case of mAbs 12.8 
and 12.10; mAb 1E1 was 10-fold less potent (data not shown). 
To confirm that the inhibition was a direct effect of antibody 
binding to MSP-1, we made use of the earlier observations 
of Wilson  et  al.  (24).  These authors  used  a  two-site RIA 
to show that  the binding of mAb  12.8  to purified  MSP-1 
was blocked when any one of mAbs 2.2,  7.5,  or 12.10 oc- 
cupied their epitopes.  Similarly, binding of mAb 12.10 was 
blocked by the binding of mAbs 12.8 and 7.5, but not by 
Figure  3.  mAbs which do not inhibit MSP-1 processing  can competi- 
tively block the activity of  mAbs which do inhibit processing. Merozoites, 
either untreated or pretreated on ice with mAbs 2.2, 7.5, and 111.4, were 
incubated at 37~  in the presence of the processing  inhibitory mAbs 12.8, 
12.10, or 1E1 to assess the effects of pretreatment on processing inhibi- 
tion. Shown are Western blots indicating that: the processing inhibitory 
effects of mAb 12.8 were blocked by pretreatment with  mAbs 2.2 and 
7.5, but not 111.4; the inhibitory effects of mAb 12.10 were blocked only 
by mAb 7.5; and the inhibitory effects ofmAb 1E1 were blocked  by mAbs 
7.5 and 111.4. These results were completely reproducible in six separate 
experiments. 
Figure  4.  Antibodies reactive with MSP-119  are bound by merozoites 
and carried  into the invaded  erythrocyte.  Direct  immunofluorescence  analysis 
of erythrocytes invaded by FCB-1 merozoites in the presence of (top) no 
added antibody or (bottom) mAb 12Dll. Fluorescent  intraceUular ring stage 
parasites are clearly evident in the bottom panel. Identical results were 
obtained with mAbs 111.4, 111.2, 2F10, and 1E1, but not mAb 89.1 (not 
shown). T9/96 ring stage parasites formed in the presence of mAbs 111.4 
and 121)11 did not possess detectable bound antibody (not shown). 
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on processing could be specifically blocked in a manner con- 
sistent with  these data.  Fig. 3  shows that  pretreatment  of 
merozoites with mAbs 2.2 or 7.5 blocked the inhibitory ac- 
tivity of mAb 12.8.  In the case of mAb 12.10, pretreatment 
with mAb 7.5, but not mAb 2.2, blocked its activity. Pretreat- 
ment with mAb 111.4 had no effect on the activity ofmAbs 
12.8 and 12.10, but did block the activity ofmAb 1E1, indi- 
cating that  1E1 binds an epitope distinct from those recog- 
nized by mAbs 12.8 and 12.10. The effects of all three mAbs 
were, however, blocked by pretreatment with mAb 7.5, sug- 
gesting  that  the three epitopes are adjacent. 
We have previously reported  that  mAbs  12.8 and  12.10 
prevent erythrocyte invasion when added to in vitro cultures 
of P.fakiparum (2). When purified mAbs 111.4, 111.2, 12Dll, 
2F10, and 1E1 were assayed for their ability to inhibit inva- 
sion in cultures of parasite strains FCB-1 or T9/96, no inhi- 
bition was seen at antibody concentrations of ~<2 mg ml- 1. 
Since it seemed unlikely that under these conditions invading 
merozoites were completely evading the antibody, we ana- 
lyzed intracellular ring-stage parasites  from these cultures for 
the presence of antibody. Newly parasitized cells were ace- 
tone fixed and probed with a FITC-conjugated anti-mouse 
IgG. Fig. 4 shows that a strong rim of fluorescence was de- 
tected associated with the intracellular parasites.  No fluores- 
cence was seen with T9/96 rings produced in the presence 
of mAbs  111.4 and 12Dll  (data not  shown).  These mAbs 
recognize epitopes not present on the MSP-1 allele expressed 
by T9/96  (22).  Furthermore,  parasites allowed to undergo 
invasion in the presence of mAb 89.1,  which recognizes  a 
conserved epitope on a fragment of MSP-1 which is shed after 
secondary processing (16, and Fig. 1), did not show fluores- 
cence.  The antibody associated with the intracellular  rings 
had bound specifically to the invading merozoite surface, and 
was not the result of nonspecific incorporation of fluid phase 
antibody into the parasitophorous vacuole during invasion. 
These results prove that  malaria merozoites can success- 
fully invade erythrocytes despite the presence of surface-bound 
antibody, and suggest that for such antibody to prevent inva- 
sion it must mediate some additional effects deleterious to 
the parasite.  We propose that  inhibition  of secondary pro- 
cessing of MSP-1 is one such effect. This is the first demon- 
stration of a parasite enzymic activity susceptible to modifica- 
tion by antibodies which prevent erythrocyte invasion. It is also 
the first evidence that the fine specificity of antibodies directed 
towards a small region of MSP-1 can determine their func- 
tion.  The observation that  antibodies which do not affect 
processing can block the inhibitory  activity of other anti- 
bodies could explain the paradoxical findings  that  individ- 
uals in malaria-endemic areas may support significant para- 
sitemias despite the presence of high plasma levels of naturally 
acquired antibodies to MSP-1 (25);  the relative concentra- 
tions and affinities of processing inhibitory and blocking an- 
tibodies may determine the overall  effect on cleavage of the 
MSP-1 complex from the surface of released merozoites, and 
in turn the ability of the parasites to invade erythrocytes. This 
hypothesis can now be tested experimentally using the anti- 
bodies and the processing assay described here.  MSP-1 is a 
promising candidate for inclusion in a subunit malaria vac- 
cine  (15).  The  assay  described  may  therefore  provide  a 
quantifiable prediction of resistance to blood-stage infection, 
which will be of use in malaria vaccine trials with MSP-1. 
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